Argus Downgrades Novo Nordisk A/S (NVO) to Hold From Buy

Novo Nordisk A/S (NYSE:NVO) is one of the best pharma stocks to invest in. Argus analyst Jasper Hellweg downgraded Novo Nordisk A/S (NYSE:NVO) to Hold from Buy on December 8, without assigning a price target. The analyst told investors in a research note that the company is experiencing a drop in marketshare in its GLP-1 drug category, including Ozempic and Wegovy. Berenberg Lowers Novo Nordisk (NVO) Price Target to DKK 400, Maintains Buy Rating It is also agreeing to bring the prices of these drugs down ...